Venus Remedies Limited has received its first patent from Canada for its novel antibiotic adjuvant entity Vancoplus. The patent has been granted by the Canadian patent office and is valid up to May 2027. The company is planning to launch the product in Canada in the next two years.
“We are really enthusiastic over the receipt of this Canadian patent for Vancoplus, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus Aureus (MRSA) infection rates in Canada”, said Dr. Manu Chaudhary, JMD, director- research, Venue Remedies.
As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), the community acquired MRSA cases have increased significantly from 19.5 per cent in 2007 to 38.1 per cent in 2010. Various studies and surveys conducted in Canada state that almost 40 per cent of the MRSA cases have arisen from the community with increase in MRSA infection amongst children and young adults who have no hospital contact or exposure.
Dr Mufti Suhail Sayeed, sr. vice president at Venus Medicine Research Centre (VMRC) stated that Vancoplus is an ‘Antibiotic Adjuvant Entity’ (AAE) constituting Ceftriaxone plus Vancomycin along with an adjuvant which restricts the production of toxin by MRSA pathogens and is highly effective in combating MRSA along with other advantages of reduced treatment time, cost and adverse effects.
The company has been marketing Vancoplus successfully in India and few of the merging markets across the globe. Venus Remedies' Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian Regulatory authorities to market the drug.